Roche prices cancer drug at $17K a month

Roche has priced its cancer treatment Rozlytrek at $17,050 per month, about half the cost of a similar drug sold by Eli Lilly and Bayer, according to STAT.

Rozlytrek, approved Aug. 15, targets solid tumors that show rare genetic defects called NTRK gene fusions and ROS1-positive non-small cell lung cancer. 

Eli Lilly and Bayer's drug Vitrakvi is priced at $32,800 per month. It also treats tumors with NTRK gene fusions. 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars